<DOC>
	<DOCNO>NCT02349009</DOCNO>
	<brief_summary>1:1 active treatment : placebo , blind trial , evaluate effect 4-week treatment period topical C-82 skin expression two gene biomarker surrogate ( THBS1 COMP ) modify Rodnan skin score ( MRSS ) . Study subject randomize apply active study medication daily 4 week either right leave forearm placebo contralateral forearm .</brief_summary>
	<brief_title>Trial Topical C-82 Systemic Sclerosis - A Phase I/II Biomarker Safety Trial</brief_title>
	<detailed_description>1:1 active treatment : placebo , blind trial , evaluate effect 4-week treatment period topical C-82 skin expression two gene biomarker surrogate ( THBS1 COMP ) modify Rodnan skin score ( MRSS ) . Study subject randomize apply study medication daily 4 week either right leave forearm . All subject apply placebo ( i.e. , topical gel without C-82 ) contralateral forearm . Both physician subject blind treatment arm assignment . Skin biopsies take mid-forearm arm baseline four week study drug test biomarker gene expression ; instruction supply provide site . Safety assessment extend 4 week final dose study drug/placebo .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>meet American College Rheumatology criterion systemic sclerosis diffuse cutaneous involvement ( clinical skin involvement proximal forearm knee , include face ) . Disease duration &lt; 36 month since onset first SSc manifestation Raynaud 's phenomenon , patient progressive disease base new worsen skin disease base physician assessment . local skin score bilateral forearm ≥ 2. MRSS ≥ 12. stable dose immunosuppressive cyclophosphamide high dose steroid ( excluded treatment ) least one month course study treatment . Subjects childproducing potential must agree use effective contraception least 3 month last treatment . Receiving treatment part interventional clinical trial within 4 week screen 5 halflives investigational drug ( whichever longer ) . Ongoing use high dose steroid ( &gt; 10mg/day prednisone equivalent ) unstable steroid dose past 4 week . Use topical cream gel forearm area within past month course study treatment . UV light therapy 4 week study period . Treatment cyclophosphamide within past month course study treatment . Known active bacterial , viral fungal mycobacterial , infection history malignancy within past 2 year . Moderate severe hepatic impairment , . Scleroderma renal crisis within 4 month creatinine great 2.0 . Pregnancy . Nursing mother exclude . Gastrointestinal involvement require total parenteral nutrition hospitalization within past 3 month pseudoobstruction Moderately severe pulmonary disease FVC &lt; 40 % , DLCO &lt; 30 % predict evidence progressive lung disease manifest decrease FVC 10 % previous year . Moderately severe cardiac disease clinically significant heart failure , unstable angina . AST ALT &gt; 2.5 x Upper Limit Normal . Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) . Patients Gilbert 's Disease may include total bilirubin ≤ 3.0 mg/dL . significant medical psychosocial problem warrant exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
</DOC>